FACTORS ASSOCIATED WITH INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN MOROCCAN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Hammou, O. [1 ]
Chennouf, F. [1 ]
Azzouzi, H. [1 ]
Linda, I. [1 ]
机构：
[1] Mohammed I Univ, Mohammed Univ Hosp 6, Dept Rheumatol, Oujda, Morocco
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.5633
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0293
引用
收藏
页码：1441 / 1441
页数：1
相关论文
共 50 条
  • [21] Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs
    Inoue, Mariko
    Kanda, Hiroko
    Tateishi, Shoko
    Fujio, Keishi
    ARTHRITIS CARE & RESEARCH, 2020, 72 (07) : 942 - 949
  • [22] Factors Associated With the Initiation of Disease-Modifying Antirheumatic Drugs in Newly Diagnosed Rheumatoid Arthritis: A Retrospective Claims Database Study
    Bonafede, Machaon M. K.
    Fox, Kathleen M.
    Johnson, Barbara H.
    Watson, Crystal
    Gandra, Shravanthi R.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 457 - 467
  • [23] Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Mittal, Niti
    Mittal, Rakesh
    Sharma, Aman
    Jose, Vinu
    Wanchu, Ajay
    Singh, Surjit
    SINGAPORE MEDICAL JOURNAL, 2012, 53 (08) : 532 - 536
  • [24] Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study
    Natalia Mena-Vazquez
    Sara Manrique-Arija
    Lucía Yunquera-Romero
    Inmaculada Ureña-Garnica
    Marta Rojas-Gimenez
    Carla Domic
    Francisco Gabriel Jimenez-Nuñez
    Antonio Fernandez-Nebro
    Rheumatology International, 2017, 37 : 1709 - 1718
  • [25] MEDICATION ADHERENCE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: A REGISTER STUDY
    Joensuu, J. T.
    Aaltonen, K. J.
    Valleala, H.
    Puolakka, K.
    Yli-Kerttula, T.
    Varjolahti-Lehtinen, T.
    Sokka, T.
    Blom, M.
    Nordstrom, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 882 - 883
  • [26] BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS PRESCRIPTION OVER TIME IN A COHORT OF EARLY RHEUMATOID ARTHRITIS PATIENTS
    Fedele, A. L.
    Melpignano, F.
    Bruno, D.
    La Ferrara, R.
    D'agostino, M. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 603 - 603
  • [27] Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study
    Mena-Vazquez, Natalia
    Manrique-Arija, Sara
    Yunquera-Romero, Lucia
    Urena-Garnica, Inmaculada
    Rojas-Gimenez, Marta
    Domic, Carla
    Gabriel Jimenez-Nunez, Francisco
    Fernandez-Nebro, Antonio
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (10) : 1709 - 1718
  • [28] Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
    Li, Ko-Jen
    Chang, Chia-Li
    Hsin, Chih-Yi
    Tang, Chao-Hsiun
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [29] Early Versus Delayed Initiation of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis.
    Van Doornum, Sharon
    Roberts, Lynden
    Reed, Mark D.
    Liew, Danny
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S781 - S781
  • [30] Factors associated with discontinuation of glucocorticoids after starting biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Inoue, Mariko
    Kanda, Hiroko
    Tateishi, Shoko
    Fujio, Keishi
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 58 - 63
12345